AtaiBeckley to Be Acquired by Eli Lilly for $6.75 Cash Plus Up to $2.50 CVR
AtaiBeckley entered into a definitive merger agreement for its acquisition by Eli Lilly, offering $6.75 per share in cash plus a contingent value right of up to $2.50 per share based on clinical and regulatory milestones. The deal will be executed via a merger of Lilly subsidiary Albali Acquisition…